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Purpose: To correlate the severity of bronchiectasis in children with
cystic fibrosis with clinical and microbiologic variables in




After institutional review board approval and parental in-
formed consents were obtained, a HIPAA-compliant longi-
tudinal epidemiologic evaluation was performed in pa-
tients with cystic fibrosis who were enrolled in the Wiscon-
sin trial of newborn screening from 1985 to 2009. Thin-
section chest computed tomography (CT) was used in a
prospective cross-sectional design to study patients rang-
ing in age from 6.6 to 17.6 years (mean, 11.5 years).
Thin-section CT scores were determined objectively on
coded images by multiple raters in a standardized fashion.
Microbiologic data were obtained by means of culture of
respiratory secretions by using methods for differentiation
of Pseudomonas aeruginosa (PA) as either nonmucoid or
mucoid.
Results: Eighty-three percent of patients (68 of 82) showed bron-
chiectasis of varying severity. Of 12 potential risk factors,
only respiratory infection with mucoid PA correlated sig-
nificantly with bronchiectasis (P  .041).
Conclusion: The severity of bronchiectasis in children with cystic fibro-
sis is significantly related to respiratory infection with mu-
coid PA; attempts to prevent bronchiectasis should include
reducing exposure to and early eradication of PA.
 RSNA, 2009
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Patients with cystic fibrosis (CF) aresusceptible in early childhood tochronic lung disease associated
with recurrent respiratory infections due
to unusual respiratory pathogens such as
Staphylococcus aureus and Pseudomonas
aeruginosa (PA) (1). At a variable age,
patients with CF will develop obstructive
pulmonary dysfunction (2). In addition,
the majority of children with CF show
structural bronchopulmonary abnormali-
ties (3–5), including bronchiectasis, mu-
cous plugging, peribronchial thickening,
air trapping, and parenchymal opacities.
Bronchiectasis is an early and prominent
feature of CF lung disease. Bronchiectasis
is considered an irreversible abnormality
(4,6) and thus indicates the presence of
permanent damage to the lungs. Chrono-
logically, bronchiectasis is the first irre-
versible change seen in children with CF
(7). Because the identification of bronchi-
ectasis indicates that treatment can no
longer be expected to return the status of
the lungs to normal, the prevention of
bronchiectasis is of great importance in
the care of the child with CF.
Although there has been limited lon-
gitudinal research focused on bronchi-
ectasis determinants in patients with CF
(4), cross-sectional and short-term
studies suggest that bronchiectasis cor-
relates with significantly increased air-
ways obstruction (8,9). In addition,
Evans et al (6) reported that patients
with bronchiectasis “who become colo-
nized by P aeruginosa have poorer lung
function when first colonized than those
colonized by other organisms.” Despite
its obvious clinical importance, the epi-
demiology of bronchiectasis has not
been well described in CF.
Computed tomography (CT) is the
imaging modality of choice to identify
and quantify bronchiectasis (10) and
the other morphologic changes seen
with CF lung disease. Pulmonary func-
tion tests (PFTs) are the most widely
used means of assessing CF lung dis-
ease, but CT scanning has been shown
to demonstrate bronchiectasis in chil-
dren with normal PFT findings (7) and
to demonstrate progressive disease
when PFT results remained stable (11).
CT scanning uses ionizing radiation and
so involves the risk of radiation expo-
sure but is otherwise noninvasive. The
findings cited above support CT scan-
ning as the best available method to
identify and quantitate bronchiectasis
and other features of CF lung disease in
order to assess the determinants of
bronchiectasis in children with CF.
Because of Wisconsin’s long-term
randomized clinical trial (12) of early
diagnosis through newborn screening,
and especially its unique longitudinal ep-
idemiology component (13), we were
presented with an unprecedented op-
portunity to investigate the determi-
nants of bronchiectasis in children with
CF. Our prospective design included
thin-section CT scanning in all patients
giving consent after they had reached at
least 6 years of age. The hypothesis we
addressed regarding the epidemiology
of bronchiectasis is that extrinsic clini-
cal factors will determine its severity.
More specifically, on the basis of our
earlier observations (14), we postulated
that PA-associated respiratory infec-
tions would contribute significantly to
the severity of bronchiectasis.
Materials and Methods
Patients and Design
The Wisconsin longitudinal cohort study of
early diagnosis, a collaborative multidisci-
plinary project involving the two CF cen-
ters of Wisconsin and all newborns, has
been described in detail elsewhere
(12,13,15). By using randomized new-
born screening from April 1985 through
June 1994, we enrolled 149 children in
whom CF was diagnosed after a sweat
chloride level of 60 mmol/L or greater
and for whom written informed consent
was provided by their parents; thus, pa-
tient accrual occurred over approxi-
mately a decade. Two groups were then
managed and assessed similarly with an
evaluation and treatment protocol (13):
an early diagnosis, screened group and a
concurrent control group with diagnosis
obtained by means of the traditional
method after signs and/or symptoms of
CF appeared or a positive family history





CF  cystic fibrosis
FEF25%–75%  midexpiratory phase of forced expiratory flow
FEV1  forced expiratory volume in 1 minute
FVC  forced vital capacity
PA  Pseudomonas aeruginosa
PFT  pulmonary function test
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Advances in Knowledge
 Of 12 potential risk factors, only
respiratory infection with mucoid
Pseudomonas aeruginosa (PA)
correlated significantly with the
severity of bronchiectasis in chil-
dren with cystic fibrosis (CF).
 CT scores correlated significantly
with mucoid PA, while no signifi-
cant correlations were seen be-
tween pulmonary function tests
(the most commonly used assess-
ment of lung status) and other
potential etiologic factors for
bronchiectasis and CF lung dis-
ease in children.
Implications for Patient Care
 Our findings suggest that averting
infection with mucoid strains of
PA may be critical in preventing
bronchiectasis and pulmonary
deterioration in children with CF.
 In young children, chest imaging
is approximately fourfold more
sensitive than pulmonary function
testing for the evaluation of CF
lung disease in children.
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“unblinding” process in which all the con-
trol subjects were identified (12,13). Care
was provided by using standard methods
of the era (13), with physicians and
nurses unaware of the group to which the
patient was assigned (3).
The longitudinal evaluations included
quarterly, systematic assessment of respi-
ratory symptoms; cultures of respiratory
secretions at least every 6 months; semi-
annual PFTs beginning at 4 years of age;
and annual chest radiographs. An associ-
ated cross-sectional thin-section CT study
was added in 2000. Of the original 149
patients, 104 who continued to receive
care in the protocol at the two CF centers
were contacted. Enrollees who were 6
years of age and older and who gave ad-
ditional informed consent (directly or
through their parents) underwent thin-
section CT scanning performed as de-
scribed below. More specifically, 94 pa-
tients gave consent to a CF center physi-
cian who described the study and chest
CT procedure; however, nine patients
never came for their scheduled appoint-
ment and three scans could not be used.
Thus, 82 patients participated in the thin-
section CT study. The CT scanning in this
research protocol was performed when
the patients were at their baseline health
status and not for clinical indications. The
characteristics of the patients are pro-
vided in Table 1. The randomized control
trial and all associated studies such as
chest imaging were Health Insurance
Portability and Accountability Act–com-
pliant and were approved by the institu-
tional review boards of the University of
Wisconsin–Madison, the Children’s Hos-
pital of Wisconsin, and Cincinnati Chil-
dren’s Hospital, Ohio.
Chest CT Scanning and Scoring
Procedures
One chest CT scan (Lightspeed; GE Med-
ical Systems, Milwaukee, Wis) was ob-
tained in each of the 82 patients by using
a thin-section technique (1.25-mm sec-
tion thickness, 120 kVp, 40 mAs, and
bone reconstruction algorithm). Inspira-
tory images were obtained at 10-mm in-
tervals from apices through lung bases.
Six expiratory images were obtained,
evenly spaced from 1 cm above the top of
the aortic arch to 2 cm above the higher
hemidiaphragm (16). In a 10-year-old
child this protocol was calculated to pro-
duce an average radiation exposure of ap-
proximately 0.55 mSv. All studies were
performed without sedation by using ver-
bal commands and voluntary respiratory
control. All 82 CT scans scored were of
good quality as indicated by the lack of
patient motion or any other factor that
would interfere with recognition of bron-
chiectasis, with no patients excluded due
to inadequate image quality. Cooperation
with instructions by the three patients
younger than 8 years, who all produced
good-quality inspiratory and expiratory
series, was likely facilitated by the PFT
training these patients receive beginning
at age 4–6 years.
Hard-copy images were scored inde-
pendently by one adult thoracic radiolo-
gist (L.S.B.) and two pediatric radiolo-
gists (A.S.B. and one nonauthor), all with
more than 5 years postfellowship experi-
ence, who trained together by using a
previously described scoring system (16).
Each lobe, with the lingula scored as a
separate lobe, was evaluated for the ex-
tent and severity of bronchiectasis, mu-
cous plugging, peribronchial thickening,
parenchymal opacity, ground-glass opac-
ity, cysts or bullae, and air trapping. For
the parenchymal abnormalities, the score
for each lobe was determined by the de-
gree of involvement of the lobe demon-
strating the abnormality, using a scale of
1–3. For the remaining findings, the se-
verity of each finding was assessed by us-
ing predetermined criteria, and the sever-
ity score was multiplied by the degree of
involvement as for parenchymal disease.
For bronchiectasis, the score reflects the
average size of dilated bronchi, the size of
the largest bronchus, and the volume of
each lobe containing dilated bronchi.
Bronchiectasis was defined as an airway
lumen diameter greater than the diame-
ter of the accompanying artery or an ar-
tery equidistant from the hilum, nonta-
pering bronchi, or a bronchus extending
to the pleural surface. Mucous plugging
was defined as soft-tissue attenuation fill-
ing the bronchial lumen and was identi-
fied by multiple factors including relation-
ship to aerated bronchi, location adjacent
to pulmonary arteries, and linear or
branching configuration not correspond-
Table 1
Characteristics of Patients Participating

















Pancreatic sufficiency 13 (16)















No PA 16 (20)
Nonmucoid PA 32 (39)










No. of days with infection 0–90 days
No. of days with hospitalization 0–18 days
Age of patients (y)
Mean  standard deviation 11.5  .3
Median 11.3
Range 6.6–17.6
Note.—Except where otherwise indicated, data are the
numbers of patients (n  82). Data in parentheses are
percentages.
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ing to pulmonary vessels. The details of
the scoring system have been previously
reported (17,18).
Reference images chosen (A.S.B.)
from prior research subjects were used
for quality control purposes and thus
were selected from thin-section CT
scans obtained in children with CF who
were not participants in this study. Ref-
erence images were chosen to repre-
sent the different findings used in the
scoring system and a range of disease
severity. The agreement of the three
radiologists performing the scoring was
excellent, as reported elsewhere (16).
Other Clinical and Laboratory
Assessments
Genotype was determined by means of
DNA analysis (19). Pancreatic func-
tional status was assessed with a 3-day
fecal fat study. According to protocol,
respiratory secretions were obtained
and cultured during CF center visits ev-
ery 6 months or whenever clinically in-
dicated according to the judgment of the
patient’s physician. The average inter-
val for obtaining protocol-based and
clinically indicated cultures was 3.3
months. Most of these respiratory se-
cretions were obtained from vigorous
oropharyngeal swabs during forced
coughing. Specimens were plated on
agar and cultured, with particular atten-
tion given to identifying Haemophilus
influenzae, S aureus, and PA. The PA
identification process included detec-
tion of nonmucoid and mucoid species,
as described previously (15). In addi-
tion, cultures were examined for the
presence of Aspergillus fumigatus.
Lung function measurement by means
of spirometry was obtained every 6
months, beginning at approximately 4
years of age. The quality of the data was
ensured by using the pediatric alternate
spirometry system (P.M.F.), as described
in detail elsewhere (3). Thus, all pulmo-
nary function data evaluated in this study
were of good quality. Predicted values
were from reference equations by Wang
et al (20).
Statistical Analyses
The effects of baseline risk factors, in-
cluding patient group, CF center, sex,
genotype, pancreatic status, and meco-
nium ileus status were examined. Time-
dependent risk factors, including aero-
sol antibiotic use, chronic antibiotic use
(prophylactic antibiotics, defined as an-
tibiotics prescribed for more than 30
days and unrelated to infection), regular
antibiotic use (prescribed in response to
acute infection), PA status, S aureus
status, H influenzae status, A fumigatus
status, days with infections before a
visit (visits occurred every 3 months),
days with hospitalization before a visit,
and age of patients were documented 6
months before the CT study was per-
formed. Status of pathogens (eg, non-
mucoid PA and mucoid PA) was scored
as 0 until the first positive culture and 1
thereafter. The effects of these risk fac-
tors on the cross-sectional CT bronchi-
ectasis scores and CT total scores were
assessed by means of a general linear
model in which all risk factors were ex-
amined together. The categoric vari-
ables (grouping factors) included pa-
tient group, CF center, sex, genotype,
pancreatic status, meconium ileus sta-
tus, aerosol antibiotics use, chronic an-
tibiotic use, regular antibiotic use, PA
status, S aureus status, H influenzae sta-
tus, and A fumigatus status. The contin-
uous variables (covariates) included
days with infections, days with hospital-
ization, and age of patients. In the gen-
eral linear model, we analyzed all risk
factors together in one multiple linear
model, so adjustment for multiple
comparisons arising from the multiple
risk factors is not needed. The col-
linearity among continuous variables
were checked with the COLLIN col-
linearity option (SAS Institute, Cary,
NC) in a regression model with thin-
section CT bronchiectasis and total
scores as dependent variables, and the
proportion of variance greater than 0.5
is considered as collinearity. We did not
see significant collinearity.
As we reported in Li et al (15), nonmu-
coid PA infection occurred after absence of
PA infection, and mucoid PA infection oc-
curred after nonmucoid PA infection. They
are three distinct stages in the life course of
patients with CF (21,22). We were only
interested in two comparisons: nonmucoid
PA versus no PA infection and mucoid PA
versus nonmucoid PA. Our prospective hy-
pothesis was that bronchiectasis at the non-
mucoid PA stage is worse than bronchiec-
tasis at the absence of PA infection stage
and that bronchiectasis at the mucoid PA
stage is worse than bronchiectasis at the
nonmucoid PA stage. Thus, we examined
only these two comparisons.
Correlation between thin-section
CT bronchiectasis scores and the con-
current PFT findings were examined by
using Pearson partial correlation coeffi-
cients adjusted for all risk factors. Then,
the effects of the above various risk fac-
tors on the concurrent PFT findings
were assessed by means of a general
linear model. Since each of the four lung
function outcomes is evaluated as a sci-
entifically distinct question, multiple
comparison adjustment for multiple
outcomes is not needed. The robust lo-
cally weighted regression function was
used to estimate the mean response in
thin-section CT bronchiectasis scores
and total scores in different PA groups as
a function of age. Results were consid-
ered statistically significant if P  .05.
Results
Patient Characteristics
The characteristics of the 82 patients
evaluated in the cross-sectional chest CT
imaging study are summarized in Table 1.
In general, they were a typical population
of children with CF, with about half of the
CF cases diagnosed through screening
(39 of 82 children) and the remainder of
the diagnoses being made after the devel-
opment of signs or symptoms of the dis-
ease (43 of 82 children). Gastrointestinal
abnormalities were present in the ex-
pected proportion (24% with meconium
ileus and 84% with pancreatic insuffi-
ciency). Aggressive management was
used to prevent malnutrition (13). Geno-
types of the children in this study were
similar to those of U.S. CF patients as a
whole: 57% (47 of 82 children) F508del
homozygotes, 38% (31 of 82) F508del
compound heterozygotes, and 5% (four
of 82) lacked this mutation. At the time of
CT scanning, the patients ranged in age
from 6.6 to 17.6 years (mean, 11.5 years;
median, 11.3 years). The mean ages (
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standard deviation) were 11.5 years 
0.48 (range, 7.5–17.6 years) for female
patients and 11.5 years  0.45 (range,
6.5–17.1 years) for male patients (P 
.94). As shown in Table 1, respiratory
secretion cultures were often positive,
and 89%, 87%, and 80% showed S au-
reus, H influenzae, and PA, respectively,
at the time of the chest CT scan. The
PA-positive cultures showed nonmucoid
(39%) and mucoid (41%) species.
Potential Risk Factors
We found that 83% (68 of 82) of the
patients had bronchiectasis. The effects
of various risk factors on thin-section
CT bronchiectasis scores are shown in
Table 2. General linear model shows that
a significantly higher CT bronchiectasis
score (P  .41) was observed in patients
with mucoid PA compared to patients
with nonmucoid PA and that there is no
significant difference in CT bronchiectasis
scores between the group with nonmu-
coid PA and the group with no PA infec-
tion. CT bronchiectasis scores increased
significantly (P  .012) with age. Analysis
of the other potential risk factors revealed
no significant effects. Figure 1 demon-
strates graphically the prominent role of
mucoid PA in the development of bron-
chiectasis in children with CF. The CT
bronchiectasis scores are similar in the
patient group with nonmucoid PA and the
patient group with no PA infection. In
contrast, the group with mucoid PA had
apparently higher CT bronchiectasis
scores than did the group with nonmu-
coid PA. Figure 2 demonstrates graphi-
cally the effect of mucoid PA and nonmu-
coid PA on the thin-section CT total
scores. The total scores are similar in pa-
tients with nonmucoid PA and patients
with no PA infection. In contrast, patients
with mucoid PA had higher thin-section
CT total scores than did patients with
nonmucoid PA. Figure 3 illustrates the
thin-section CT appearance and scores in
representative children without PA infec-
tion, with nonmucoid PA infection, and
with mucoid PA infection.
Correlations of Lung Disease Measures
Table 3 shows the Pearson correlation
coefficients between CT bronchiectasis
scores and the concurrent pulmonary
function measurements. The most com-
monly used measure of lung function, per-
centage predicted FEV1, was above 0.8 in
82.3% of patients (67 of 82) at the time of
the chest thin-section CT procedure, and
therefore the group as a whole had mild
pulmonary dysfunction. Correlation coef-
ficients for the various pulmonary func-
Table 2
General Linear Model Analyses of the Thin-Section CT Bronchiectasis Scores and Total Scores




Screened .26  .21 vs Control (.22) .39  .58 vs Control (.50)
Center
Madison
Milwaukee .38  .25 vs Madison (.12) .40  .67 vs Madison (.56)
Sex
Male
Female .09  .21 vs Male (.68) .28  .58 vs Male (.64)
Genotype
F508del/F508del .27  .56 vs Other/other (.63) .16  1.52 vs Other/other (.92)




Pancreatic insufficiency .10  .38 vs Sufficiency (.80) .48  1.00 vs Sufficiency (.64)
Meconium Ileus
No




Yes .42  .43 vs No (.33) 1.16  1.08 vs No (.29)
Chronic antibiotic use
No
Yes .01  .31 vs No (.98) .05  .85 vs No (.95)
Regular antibiotic use
No
Yes .05  .27 vs No (.87) .12  .74 vs No (.88)
PA status
No PA
Nonmucoid PA .21  .32 vs No PA (.52) .47  .85 vs No PA (.58)
Mucoid PA .55  .27 vs Nonmucoid (.041) 1.77  .73 vs Nonmucoid (.018)
S aureus
No
Yes .07  .37 vs No (.84) .06  1.00 vs No (.95)
H influenzae
No
Yes .19  .32 vs No (.57) .59  .89 vs No (.51)
A fumigatus
No
Yes .32  .29 vs No (.27) .73  .78 vs No (.36)
Days with infection .01  .01 per day (slope) (.30) .00  .03 per day (slope) (.94)
Days with hospitalization .06  .05 per day (slope) (.28) .25  .14 per day (slope) (.07)
Age of patients (y) .11  .04 per year (slope) (.012) .28  .12 per year (slope) (.023)
Note.—Data are differences  standard error, and numbers in parentheses are P values.
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tion results—percentage predicted FEV1,
percentage predicted FVC, percentage
predicted FEV1/FVC, and percentage
predicted FEF25%–75%—ranged from
0.44 to 0.59 (P  .001). The negative
correlation indicates that the higher the CT
bronchiectasis score, the lower the PFT re-
sult. These midrange correlation coeffi-
cients support our understanding that while
there is significant correlation between
thin-section CT and PFT findings, the two
modalities reflect different information.
Pulmonary Function Measurements
Table 4 shows that there are no significant
differences in percentage predicted FEV1,
percentage predicted FVC, percentage pre-
dicted FEV1/FVC, and percentage pre-
dicted FEF25%–75% in patients with nonmu-
coidPAcomparedwithpatientswithoutPA
infection. However, percentage predicted
FEV1 showed a strong trendof lower values
in patients with mucoid PA compared with
those with nonmucoid PA (P  .07).
Discussion
Children with CF are born with mor-
phologically normal lungs. A cycle of in-
flammation and infection begins within
the first few months of life that leads to
progressive lung damage (3,14,15).
Lung disease is the cause of death of
95% of people with CF, with a mean
survival currently at 37 years of age
(23). To plan health care to slow or stop
this progressive damage, it is essential
to know which potential risk factors are
associated with more severe lung dis-
ease so that these factors can be specif-
ically addressed.
Children with CF are prone to de-
velop irreversible lung disease at a
young age (3,5). Long-term epidemio-
logic studies show that even when the
diagnosis is made early through new-
born screening and malnutrition is pre-
vented (13), CF patients infected with
respiratory pathogens are likely to de-
velop chronic cough and radiographic
chest abnormalities (2,3,14). However,
to our knowledge, prior to this study the
potential determinants of specific mor-
phologic abnormalities such as bronchi-
ectasis had not been analyzed.
The results of this study indicate an
association between bronchiectasis and
mucoid PA, but do not address causation.
A causal relationship between mucoid PA
and CF lung disease, however, has been
suggested by other studies (14,15). Lon-
gitudinal studies have shown that early
colonization with mucoid PA is associ-
ated with a more rapid decline in lung
function (24), increased morbidity and
mortality (25), and a 2.6 times greater
8-year risk of death (26). Li et al (15)
found that increased cough scores,
worsening abnormalities on chest radio-
graphs, and deterioration of lung func-
tion correlated best with the transition
of patients with culture-positive nonmu-
coid PA to culture-positive mucoid PA,
suggesting a specific role for mucoid PA.
In our study, neither S aureus nor non-
mucoid PA, which are known to colo-
nize bronchiectatic airways, were asso-
ciated with increased bronchiectasis
scores. These results suggest that mu-
coid PA is more than a marker for the
presence of bronchiectasis. Mucoid
PA was the only one of 12 factors stud-
ied that was associated with increased
bronchiectasis severity. Factors that
relate to overall morbidity, such as an-
tibiotic use, days with infection, and
days with hospitalization, did not cor-
Figures 1, 2
Figure 1: Graph shows difference in the thin-section CT (HRCT) bronchiecta-
sis scores between patients with nonmucoid PA and those without PA infection
and between patients with mucoid PA and those with nonmucoid PA. The vertical
bars show average upper or lower 97.5% confidence intervals.
Figure 2: Graph shows difference in the thin-section CT (HRCT) total scores
between patients with nonmucoid PA and those without PA infection and between
patients with mucoid PA and those with nonmucoid PA.
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relate with the severity of bronchiec-
tasis.
Value of Quantitative Chest Imaging
In this study, no significant correlations
were seen between PFTs and the poten-
tial etiologic factors for bronchiectasis
and CF lung disease, while both CT
bronchiectasis score and overall disease
severity scores demonstrated significant
correlation with colonization with mu-
coid PA. This is not surprising, since
PFTs depend on the behavior of the en-
tirety of both lungs, while the anatomic
localization provided by using CT allows
reliable identification of disease affect-
ing as little as a single bronchopulmo-
nary segment. A previous study found
that bronchiectasis was found in three
or more lobes in 17% of children ages
6–10 years with normal PFT results (7).
Previous studies have demonstrated
that, in addition to being sensitive, CT
scanning is reliable and reproducible
(16,27). The current study supports the
value of CT scanning for studies investi-
gating the severity of CF lung disease in
children.
Currently, no other imaging modal-
ity, including magnetic resonance imag-
ing (28), provides the sensitivity and
specificity for the changes of CF lung
disease provided by CT scanning. The
technique used in this study resulted in
a dose of 0.55 mSv, approximately the
amount of radiation exposure from 9
weeks of background radiation. Since
this study began, the value of reducing
Figure 3
Figure 3: Representative 1.25-mm axial thin-section CT images through upper
lobes in patients with bronchiectasis scores near the mean for age and PA status.
Maximum score for each lobe is 12. Total lung score is mean of the six “lobes.”
(a) Scan in 14.7-year-old patient with culture-negative findings for PA. Arrow
shows dilated bronchus (lumen larger than accompanying vessel) in right upper
lobe (RUL). Scores: RUL bronchiectasis, 0.67; total lung bronchiectasis, 0.44; RUL
overall, 1.67; total lung overall, 1.28. (b) Scan in 15.5-year-old patient with culture-
positive nonmucoid PA. Dilated bronchi in RUL (arrows) can be compared to nor-
mal bronchi in left upper lobe. Scores: RUL bronchiectasis, 1.67; total lung bron-
chiectasis, 0.51; RUL overall, 4.5; total lung overall, 1.69. (c) Scan in 13.5-year-old
patient with culture-positive mucoid PA. Multiple markedly dilated and mucus-
filled bronchi are seen in RUL (arrows). Scores: RUL bronchiectasis, 2.25; total
lung bronchiectasis, 1.63; RUL overall, 11.25; total lung overall, 5.67.
Table 3
Pearson Partial Correlation Coefficients between CT Bronchiectasis Scores and
Concurrent PFT Measurements
PFT Measurement CT Bronchiectasis Score P Value
Pecentage predicted FEV1 .48 .007
Pecentage predicted FVC .51 .004
Percentage predicted FEV1/FVC .13 .49
Percentage predicted FEF25%–75% .21 .26
Note.—Adjusted for all variables in Table 1. FEF25%–75%  midexpiratory phase of forced expiratory flow, FEV1  forced
expiratory volume in 1 minute, FVC  forced vital capacity.
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voltage as a means of further reducing
radiation exposure has been explored
(29). It is likely that the voltage could be
reduced from 120 to 100 kVp and still
allow for adequate image quality. This
would reduce radiation exposure by an
additional 30%.
Pathogenesis of Bronchiectasis
The prevalence of bronchiectasis, its
early onset in CF, and its causes have
not been well understood. Further-
more, the lack of longitudinal bronchi-
ectasis-focused epidemiologic investiga-
tions beginning during infancy has left a
gap in knowledge about the determi-
nants of this structural lesion in children
with CF. Nevertheless, there is a body
of literature (30–33) incriminating re-
current lower respiratory tract infec-
tions in children who develop bronchi-
ectasis as a result of conditions other
than CF. Although there has been lim-
ited research on specific respiratory
pathogens and their association with
bronchiectasis, which is considered an
“orphan disease” (32), it seems that
many different bacteria and perhaps
some viruses are capable of bronchial
damage that is sufficient to cause bron-
chiectasis (30–33). However, to our
knowledge, the relationship between
PA and bronchiectasis has not been
studied in an epidemiologic investiga-
tion.
Our CF cohort data accrued over the
course of more than 20 years and analy-
ses of potential bronchiectasis determi-
nants revealed a striking observation—
only mucoid PA accounted for the irre-
versible, structural bronchopulmonary
lesion of bronchiectasis. In this study we
found that the severity of bronchiectasis
and of morphologic changes of CF lung
disease overall measured at CT scanning
is significantly related to colonization with
mucoid PA. Colonization with nonmucoid
PA and multiple other potential risk fac-
tors, including antibiotic use and days of
hospitalization, were not significantly as-
sociated with increased lung disease.
Although this is an original discovery,
perhaps it should not be surprising when
one considers the following: (a) Mucoid
PA with its protective biofilm is generally
resistant to antibiotics (15,34), (b) mu-
coid PA localizes to bronchi in CF patients
(35), and (c) mucoid PA produces many
toxins and virulence factors (36). In addi-
tion, our previous observations revealed
that mucoid PA respiratory infections ac-
celerate CF lung disease (14) and pulmo-
nary dysfunction (15). On the other hand,
our assessment of pulmonary function
data compared with thin-section CT eval-
uation demonstrated that the former sur-
rogate of CF lung disease in children is
much less sensitive (quantitatively, about
fourfold more revealing).
Clinical Implications
PA, which is ubiquitous in the environ-
ment, very effectively targets the CF
lung (34,37). The acquisition of mucoid
PA occurs only after acquisition of non-
mucoid PA (21–23), and the transition
from absence of PA infection to mucoid
PA occurs over a period of years in most
patients (15). This provides a window of
opportunity to prevent or delay the acqui-
sition of mucoid PA, which cannot be
eradicated by current antibiotics (38,39).
Accordingly, we studied a variety of
factors that could conceivably be associ-
ated with irreversible lung disease
(manifested by bronchiectasis) and
tested the hypothesis that PA would
contribute significantly. There are study
limitations, however, that relate to our
enrolled population and design. The
number of patients investigated and the
cross-sectional evaluation of 82 patients
could be limiting, as well as the geno-
type and clinical variations shown in Ta-
ble 1. In addition, the cultures of respira-
tory secretions were based largely on oro-
pharyngeal swabs, which have limited
sensitivity (34). One other limitation of
our analyses is the possible effect of col-
linearity and/or confounding among the
independent variables. The P values for
the individual terms reported in Table 2
are type III P values—that is, they reflect
the incremental gain in the model when
the term is added to a model already in-
cluding some of the other terms. As such,
a nonsignificant P value does not imply
that the term is unrelated to the outcome;
rather, it only implies that the term pro-
vides nothing more than the other terms.
The association of bronchiectasis
with mucoid PA has many implications
for diagnosis and treatment in children
with CF. Because bronchiectasis may de-
velop early during infancy (40), and new-
borns with CF are not colonized with PA,
these findings add to the arguments for
diagnosis through newborn screening
combined with aggressive care to avoid
chronic and especially mucoid PA infec-
tions. Although studies have linked mu-
coid PA to deteriorating pulmonary func-
Table 4
General Linear Model Analyses of the Cross-sectional PFT Measurements
PFT and PA Status Difference  Standard Error P Value
Percentage predicted FEV1
No PA
Nonmucoid PA 8.44  5.65 vs No PA .14
Mucoid PA 8.65  4.74 vs Nonmucoid PA .073
Percentage predicted FVC
No PA
Nonmucoid PA 6.94  5.09 vs No PA .18
Mucoid PA 6.32  4.27 vs Nonmucoid PA .14
Percentage predicted FEV1/FVC
No PA
Nonmucoid PA 2.22  2.82 vs No PA .43
Mucoid PA 3.78  2.36 vs Nonmucoid PA .12
Percentage predicted FEF25%–75%
No PA
Nonmucoid PA 14.33  11.37 vs No PA .21
Mucoid PA 13.04  9.35 vs Nonmucoid PA .17
Note.—Adjusted for all risk factors as shown in Table 1.
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tion (15,41) and early mortality (25), to
our knowledge this is the first observation
that irreversible lung structural damage is
specifically associated with mucoid PA.
Thus, care to prevent PA exposure is es-
sential, especially in infants and young
children diagnosed with CF through new-
born screening. This follow-up care com-
ponent was emphasized in the Center for
Disease Control’s recommendation for
nationwide implementation of newborn
screening (42). The risk of PA cross-
infection is substantial (25,43–46) and
the impact of early, nosocomial PA acqui-
sition may be catastrophic (25,46,47). In
addition, methods of infection control are
well described in the literature (48), but
need to be applied rigorously. Although
early recognition of nonmucoid PA is im-
portant, cultures are somewhat insensi-
tive (49) when obtained in the routine
fashion from young children with CF who
typically do not expectorate sputum
(50,51). Consequently, reliable methods
of PA serology are sorely needed (51,52).
Finally, treating nonmucoid PA with
antibiotics capable of eradicating this
organism (43,53) before mucoid trans-
formation occurs is clearly desirable to
prevent early development of progres-
sive lung disease with bronchiectasis in
children with CF. Although no long-
term placebo-controlled trial exists to
examine this, and the issue of bronchi-
ectasis prevention awaits further re-
search, several relatively short-term,
randomized controlled trials (43,53–55)
have suggested that initial colonization
of PA in the respiratory tract can be at
least temporarily eradicated by the
early use of antibiotics. Our findings
suggest that averting infection with mu-
coid strains of PA is critical in the pre-
vention of chronic bronchiectasis and
pulmonary deterioration in patients
with CF.
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